|
Mar 20
|
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
|
|
Mar 19
|
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
|
|
Mar 18
|
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
|
|
Mar 12
|
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
|
|
Feb 15
|
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 15
|
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
|
|
Feb 15
|
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
|
|
Feb 12
|
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
|
|
Sep 7
|
T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase
|
|
Aug 28
|
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs
|
|
Aug 24
|
Is T2 Biosystems a Hidden Gem or a Value Trap? An In-Depth Analysis
|
|
Apr 26
|
T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference
|